Riociguat
Back to searchMolecule Structure
Scientific Name
Riociguat
Description of the Drug
Riociguat is a stimulator of soluble guanylate cyclase indicated for the management of persistent or recurrent chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB08931
http://www.drugbank.ca/drugs/DB08931
Brand Name(s)
Adempas, Bay 63-2521
Company Owner(s)
Bayer Healthcare Pharmaceuticals Inc, Msn Laboratories Private Ltd
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Soluble guanylate cyclase | PROTEIN COMPLEX GROUP | POSITIVE ALLOSTERIC MODULATOR | CHEMBL2111348 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL245457 | |
| Human Metabolome Database | HMDB0257236 | |
| DrugBank | DB08931 | |
| PubChem: Thomson Pharma | 16393220 | |
| PubChem | 11304743 | |
| LINCS | LSM-45758 | |
| Nikkaji | J2.832.869I | |
| PDBe | GZO | |
| DrugCentral | 4807 | |
| Brenda | 11935 | 147765 |
| ChemicalBook | CB62473752 | |
| Guide to Pharmacology | 5257 | |
| rxnorm | RIOCIGUAT | ADEMPAS |
| PubChem: Drugs of the Future | 87550988 | |
| ChEBI | 76018 | |
| ZINC | ZINC000003819392 |
